Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07600749
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Malignant Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MK-4884 — DRUG
    Oral Administration

Study Details

Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.

Key Dates

Start date
Jun 18, 2026
Status verified
Jun 2026
Primary completion
Oct 4, 2029
Completion
Oct 4, 2029

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: MK-4884 Dose Escalation Schedule A
    Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met.
  • Experimental: MK-4884 Dose Escalation Schedule B
    Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met.

Primary Outcome Measure

Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) [ Time Frame: Up to approximately 21 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NEXT Oncology ( Site 0151)San AntonioTexas78229
Study Coordinator
210-568-4397

Find similar trials in San Antonio, TX

By research site
NEXT Oncology· San Antonio, TX

Related Studies